Literature DB >> 25176651

Luminal cells are favored as the cell of origin for prostate cancer.

Zhu A Wang1, Roxanne Toivanen1, Sarah K Bergren1, Pierre Chambon2, Michael M Shen3.   

Abstract

The identification of cell types of origin for cancer has important implications for tumor stratification and personalized treatment. For prostate cancer, the cell of origin has been intensively studied, but it has remained unclear whether basal or luminal epithelial cells, or both, represent cells of origin under physiological conditions in vivo. Here, we use a novel lineage-tracing strategy to assess the cell of origin in a diverse range of mouse models, including Nkx3.1(+/-); Pten(+/-), Pten(+/-), Hi-Myc, and TRAMP mice, as well as a hormonal carcinogenesis model. Our results show that luminal cells are consistently the observed cell of origin for each model in situ; however, explanted basal cells from these mice can generate tumors in grafts. Consequently, we propose that luminal cells are favored as cells of origin in many contexts, whereas basal cells only give rise to tumors after differentiation into luminal cells.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25176651      PMCID: PMC4163115          DOI: 10.1016/j.celrep.2014.08.002

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  40 in total

1.  Isolation and functional characterization of murine prostate stem cells.

Authors:  Devon A Lawson; Li Xin; Rita U Lukacs; Donghui Cheng; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

2.  Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis.

Authors:  Alan K Meeker; Jessica L Hicks; Elizabeth A Platz; Gerrun E March; Christina J Bennett; Michael J Delannoy; Angelo M De Marzo
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

3.  Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis.

Authors:  Minjung J Kim; Robert D Cardiff; Nishita Desai; Whitney A Banach-Petrosky; Ramon Parsons; Michael M Shen; Cory Abate-Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

4.  Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue.

Authors:  Y Wang; S W Hayward; A A Donjacour; P Young; T Jacks; J Sage; R Dahiya; R D Cardiff; M L Day; G R Cunha
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

5.  Prostate cancer in a transgenic mouse.

Authors:  N M Greenberg; F DeMayo; M J Finegold; D Medina; W D Tilley; J O Aspinall; G R Cunha; A A Donjacour; R J Matusik; J M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

Review 6.  Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.

Authors:  Scott B Shappell; George V Thomas; Richard L Roberts; Ron Herbert; Michael M Ittmann; Mark A Rubin; Peter A Humphrey; John P Sundberg; Nora Rozengurt; Roberto Barrios; Jerrold M Ward; Robert D Cardiff
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

7.  Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol.

Authors:  M C Bosland; H Ford; L Horton
Journal:  Carcinogenesis       Date:  1995-06       Impact factor: 4.944

8.  The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration.

Authors:  R L Noble
Journal:  Cancer Res       Date:  1977-06       Impact factor: 12.701

9.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

Authors:  Katharine Ellwood-Yen; Thomas G Graeber; John Wongvipat; M Luisa Iruela-Arispe; JianFeng Zhang; Robert Matusik; George V Thomas; Charles L Sawyers
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

10.  Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus.

Authors:  S Srinivas; T Watanabe; C S Lin; C M William; Y Tanabe; T M Jessell; F Costantini
Journal:  BMC Dev Biol       Date:  2001-03-27       Impact factor: 1.978

View more
  64 in total

Review 1.  Developing Cures: Targeting Ontogenesis in Cancer.

Authors:  Victor T G Lin; Hawley C Pruitt; Rajeev S Samant; Lalita A Shevde
Journal:  Trends Cancer       Date:  2017-01-27

Review 2.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

3.  Prostate Sphere-forming Stem Cells Are Derived from the P63-expressing Basal Compartment.

Authors:  Yanqing Huang; Tomoaki Hamana; Junchen Liu; Cong Wang; Lei An; Pan You; Julia Y F Chang; Jianming Xu; Wallace L McKeehan; Fen Wang
Journal:  J Biol Chem       Date:  2015-06-01       Impact factor: 5.157

Review 4.  Cellular plasticity: 1712 to the present day.

Authors:  Purushothama Rao Tata; Jayaraj Rajagopal
Journal:  Curr Opin Cell Biol       Date:  2016-07-30       Impact factor: 8.382

5.  Novel In Vivo model for combinatorial fluorescence labeling in mouse prostate.

Authors:  Xiaolan Fang; Kenneth Gyabaah; Bita Nickkholgh; J Mark Cline; K C Balaji
Journal:  Prostate       Date:  2015-03-08       Impact factor: 4.104

6.  OMIP-040: Optimized gating of human prostate cellular subpopulations.

Authors:  Gervaise H Henry; Nicolas Loof; Douglas W Strand
Journal:  Cytometry A       Date:  2017-08-18       Impact factor: 4.355

7.  Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.

Authors:  Shuang G Zhao; S Laura Chang; Nicholas Erho; Menggang Yu; Jonathan Lehrer; Mohammed Alshalalfa; Corey Speers; Matthew R Cooperberg; Won Kim; Charles J Ryan; Robert B Den; Stephen J Freedland; Edwin Posadas; Howard Sandler; Eric A Klein; Peter Black; Roland Seiler; Scott A Tomlins; Arul M Chinnaiyan; Robert B Jenkins; Elai Davicioni; Ashley E Ross; Edward M Schaeffer; Paul L Nguyen; Peter R Carroll; R Jeffrey Karnes; Daniel E Spratt; Felix Y Feng
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

8.  Lineage Plasticity in Cancer Progression and Treatment.

Authors:  Clémentine Le Magnen; Michael M Shen; Cory Abate-Shen
Journal:  Annu Rev Cancer Biol       Date:  2017-12-01

Review 9.  Prostate Luminal Progenitor Cells in Development and Cancer.

Authors:  Dingxiao Zhang; Shuhong Zhao; Xinyun Li; Jason S Kirk; Dean G Tang
Journal:  Trends Cancer       Date:  2018-10-01

10.  ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.

Authors:  Alba Torres; Mohammed Alshalalfa; Elai Davicioni; Anuj Gupta; Srinivasan Yegnasubramanian; Sarah J Wheelan; Jonathan I Epstein; Angelo M De Marzo; Tamara L Lotan
Journal:  Prostate       Date:  2018-05-15       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.